Local company creates a cancer therapy targeting your immune system that may change cancer treatment

ImmuneFX animal trials may lead to human trials

TAMPA - Jackson the sheltie is at the Sunshine Animal Hospital getting treatment. He was diagnosed with inoperable bladder cancer and given 190 days to live.

He's still here 500 days later and getting better.  Jackson's vet James Barry says, "He was urinating blood and had trouble going to the bathroom, and now that's all completely gone."

His owner is Sandy Soto. "You see barking, eating ,having a great time. He's totally been responsive to the treatment."

Both Jackson's owner and his vet attribute his improvement to this immunotherapy - called Immunefx.

Pat Lawman is the Chief Executive Officer of Morphogenesis.

"We insert one bacterial antigen that works as a red flag that says 'I'm foreign - I don't belong here take me out.'  In doing this, we prime and educate the immune system to recognize and then seek out and destroy cancer cells wherever they are in your body. And it does this without attacking normal cells so there are no side effects."

Lawman says they've treated 76 animals with 23 types of cancers including bone cancer, skin cancer, and lymphoma and breast cancer.

We've been following Bennie the horse - who was about to be euthanized due to melanoma. Lawman says, "We started the treatment and within a couple of months he was eating normally. Within six months some of his tumors started flaking off, and so after two years he's put on 200 pounds and he's a very happy camper."

Lawman says they're now working with the FDA and National Institutes of Health to move forward with using Immunefx on people.

Clinical trials are scheduled to begin in fall of 2014 at the University of Nebraska Medical Clinic. The patient population will be people with early stage Non- Hodgkin's Lymphoma.  Lawman says the goal is, "Our goal is to be able to manage these people's cancer.  The goal of the trial is to show no harm. There's no side effects."

What they need now is 2 million dollars to fund the trial.

Lawman thinks this type of immunotherapy will be the standard of care therapy with in the next ten years.  That chemotherapy and radiation and surgery will support immunotherapy. 

For more information:  

Qualified investors may contact: Joseph Scanlan at jscanlan@morphogenesis-inc.com

Pet owners: Steve Hazell at 813-877-7896

Veterinarians and Veterinary Oncologists: Steve Hazell at 813-877-7896 or email shazell@veterinaryoncologyservices.com



Print this article Back to Top